AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

PYC THERAPEUTICS LTD

2.140

-0.250-10.46%

Volume:4.11M

Turnover:9.03M

Market Cap:2.10B

PE:-36.21

High:2.390

Open:2.360

Low:2.110

Close:2.390

52wk High:2.930

52wk Low:1.045

Shares:983.26M

Float Shares:348.08M

Volume Ratio:1.16

T/O Rate:1.18%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.059

EPS(LYR):-0.059

ROE:-10.14%

ROA:-8.05%

PB:3.03

PE(LYR):-36.21

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

PYC Therapeutics Says First Patient Dosed in Open-Label Extension of Drug Candidate Study in Polycystic Kidney Disease

MT Newswires Live

ASX Biggest Gainers

MT Newswires Live

Why PYC Therapeutics (ASX:PYC) Is Up 10.5% After Narrowing Its Full-Year Net Loss

Simply Wall St.

PYC Therapeutics (ASX:PYC) Shares Chase Revenue Growth Despite Deep Losses

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://nz.tigermarketb.com/stock/PYC.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"PYC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PYC.AU\",,,,,undefined,":{"symbol":"PYC.AU","market":"AU","secType":"STK","nameCN":"PYC THERAPEUTICS LTD","latestPrice":2.14,"timestamp":1791868320000,"preClose":2.39,"halted":0,"volume":4108882,"delay":0,"changeRate":-0.10460251046025104,"nameEN":"PYC THERAPEUTICS LTD","floatShares":348081085,"shares":983260447,"eps":-0.0591,"marketStatus":"Not Yet Opened","change":-0.25,"latestTime":"10-13 16:12:00 AEDT","open":2.36,"high":2.39,"low":2.11,"amount":9030603,"amplitude":0.117155,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.0591,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1791932400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":2.39,"openAndCloseTimeList":[[1791846000000,1791867600000]],"volumeRatio":1.1584496143963363,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"PYC.AU","preClose":2.39,"auctionPrice":2.14,"auctionVolume":761934,"auction":3,"marketStatus":"盘后竞价","timestamp":1791868217913}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PYC.AU\",,,,,undefined,":{"symbol":"PYC.AU","floatShares":348081085,"roa":"-8.05%","roe":"-10.14%","lyrEps":-0.0591,"volumeRatio":1.1584496143963363,"shares":983260447,"dividePrice":0,"high":2.39,"amplitude":0.117155,"preClose":2.39,"low":2.11,"week52Low":1.045,"pbRate":"3.03","psRate":"80.95","week52High":2.93,"institutionHeld":0,"latestPrice":2.14,"eps":-0.0591,"divideRate":0,"volume":4108882,"delay":0,"ttmEps":-0.0591,"open":2.36,"prevYearClose":1.655,"prevWeekClose":2.45,"prevMonthClose":2.68,"prevQuarterClose":2.68,"fiveDayClose":2.68,"twentyDayClose":2.26,"sixtyDayClose":1.625,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PYC.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-11-15","symbol":"PYC.AU","defaultRemindTime":1731625200000,"type":"split","dateTimestamp":1731589200000,"forFactor":10,"toFactor":1,"ratio":10},{"market":"AU","date":"2024-03-18","symbol":"PYC.AU","defaultRemindTime":1710716400000,"type":"split","dateTimestamp":1710680400000,"forFactor":988235,"toFactor":1000000,"ratio":0.988235}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PYC.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PYC.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666511339","title":"PYC Therapeutics Says First Patient Dosed in Open-Label Extension of Drug Candidate Study in Polycystic Kidney Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2666511339","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666511339?lang=en_us&edition=fundamental","pubTime":"2026-09-11 07:28","pubTimestamp":1789082915,"startTime":"0","endTime":"0","summary":"PYC Therapeutics  said the first patient was dosed in the Part D open-label extension of the ongoing multiple-ascending dose study of its PYC-003 drug candidate in polycystic kidney disease patients, according to a Friday Australian bourse filing.This patient has been receiving the drug candidate for a period of four months and will continue to receive PYC-003 every six weeks for up to 24 months.The objective of the ongoing study is to determine the safety and tolerability profile and optimal dosing regimen of the drug candidate in a repeat-dose setting before a proposed transition to a registrational trial.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PYC.AU","BK7067","LENZ","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664033823","title":"ASX Biggest Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2664033823","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664033823?lang=en_us&edition=fundamental","pubTime":"2026-09-03 11:14","pubTimestamp":1788405296,"startTime":"0","endTime":"0","summary":"Here are the ASX-listed companies with the biggest gains on Thursday.Southgold 2 : +8%, AU$12.27Phylogica : +7%, AU$2.61OrezOne : +6%, AU$2.75Block : +5%, AU$113.81Telix Pharmaceuticals : +5%, AU$16.44Kingsgate Consolidated : +4%, AU$5.39Deep Yellow : +4%, AU$1.61Resolute Mining : +4%, AU$1.44Perseus Mining : +4%, AU$6.66Life360 : +4%, AU$19.92","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DYL.AU","SX2.AU","BK7506","360.AU","PYC.AU","BK7104","XYZ.AU","BK4139","BK7067","ORE.AU","PRU.AU","BK7016","TLX","TLX.AU","KCN.AU","BK7083","RSG.AU","BK7158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664881204","title":"Why PYC Therapeutics (ASX:PYC) Is Up 10.5% After Narrowing Its Full-Year Net Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2664881204","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664881204?lang=en_us&edition=fundamental","pubTime":"2026-09-01 05:15","pubTimestamp":1788210928,"startTime":"0","endTime":"0","summary":"PYC Therapeutics Limited recently reported full-year results for the period ended June 30, 2026, with revenue rising to A$39.68 million from A$26.17 million and its net loss narrowing to A$43.34 million compared with A$50.3 million a year earlier.\nThe improvement in both top-line revenue and loss per share suggests the business is scaling its operations while gradually reducing the financial burden on shareholders.\nWe will now examine how this combination of higher revenue and a smaller...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/why-pyc-therapeutics-asxpyc-is-up-105-after-narrowing-its-fu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/why-pyc-therapeutics-asxpyc-is-up-105-after-narrowing-its-fu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PYC.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663010707","title":"PYC Therapeutics (ASX:PYC) Shares Chase Revenue Growth Despite Deep Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2663010707","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663010707?lang=en_us&edition=fundamental","pubTime":"2026-08-30 04:19","pubTimestamp":1788034748,"startTime":"0","endTime":"0","summary":"PYC Therapeutics stock closed at A$2.25 on Friday after a strong run over the past month, yet the fresh numbers still tell a story of a biotech deep in investment mode rather than profit harvest. The headline is the loss from continuing operations of A$43.8 million over the trailing twelve months, set against revenue of A$39.7 million. For long term holders, the bigger question now is how to weigh that loss profile against a P/B of 3.2x, which sits below both direct peers and the broader...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/pyc-therapeutics-asxpyc-shares-chase-revenue-growth-despite","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/pyc-therapeutics-asxpyc-shares-chase-revenue-growth-despite","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PYC.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":7,"pageCount":1,"totalSize":27,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PYC.AU\",params:#limit:6,delay:true,,,undefined,":[]}}